Detail
LncRNA Name | LINC00673 |
Synonyms | LINC00673, HI-LNC75, HILNC75, LUCAIR1, SLNCR, SLNCR1, ERRLR01 |
Region | GRCh38_17:72403322-72592804 Sequence |
Ensembl | NA |
RefSeq | NR_036488 |
Circulating | ✘ |
Drug-resisitant | ✘ |
Prognostic | ✘ |
MiRNA | ✔ |
Variant | ✔ |
TF | ✘ |
Methylation | ✘ |
Cancer Name | pancreatic cancer |
ICD-0-3 | C25 |
Methods | qPCR, Flow cytometry assay etc. |
Sample | pancreatic cancer tissues, cell lines (BXPC-3 and CFPAC-1) |
Expression Pattern | up-regulated |
Function Description | Flow cytometry analysis indicated that LINC00673 overexpression resulted in a substantial accumulation of PDAC cells in G0/G1 phase, accompanied by a substantial decrease in the number of cells in S phase. LINC00673 is able to reinforce the interaction of PTPN11 with PRPF19, an E3 ubiquitin ligase, and promote PTPN11 degradation through ubiquitination, which causes diminished SRC-ERK oncogenic signaling and enhanced activation of the STAT1-dependent antitumor response. A G>A change at rs11655237 in exon 4 of LINC00673 creates a target site for miR-1231 binding, which diminishes the effect of LINC00673 in an allele-specific manner and thus confers susceptibility to tumorigenesis. |
Pubmed ID | 27213290 |
Year | 2016 |
Title | Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. |
External Links |
Links for LINC00673 | GenBank HGNC lncrnadb Noncode |
Links for pancreatic cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.